{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Astrocytoma%2C+Malignant&page=4", "query": { "condition": "Astrocytoma, Malignant", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 394, "total_pages": 40, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Astrocytoma%2C+Malignant&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Astrocytoma%2C+Malignant&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T11:20:11.928Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03389230", "title": "Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Malignant Glioma", "Recurrent Glioma", "Refractory Glioma", "WHO Grade III Glioma" ], "interventions": [ { "name": "HER2(EQ)BBζ/CD19t+ T cells", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2018-08-14", "completion_date": "2026-12-29", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-07T11:20:11.928Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03389230" }, { "nct_id": "NCT01113398", "title": "AMG 102 and Avastin for Recurrent Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma" ], "interventions": [ { "name": "AMG 102", "type": "DRUG" }, { "name": "Avastin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Katy Peters", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2010-08", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2015-12-10", "last_synced_at": "2026-10-07T11:20:11.928Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01113398" }, { "nct_id": "NCT00639639", "title": "Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Neoplasms of Brain" ], "interventions": [ { "name": "tetanus toxoid", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gary Archer Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2006-02-06", "completion_date": "2022-06-01", "has_results": false, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-10-07T11:20:11.928Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00639639" }, { "nct_id": "NCT00337207", "title": "Bevacizumab in Treating Patients With Recurrent or Progressive Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2006-03", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-10-07T11:20:11.928Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00337207" }, { "nct_id": "NCT05563272", "title": "89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer", "Glioblastoma Multiforme", "Cholangiocarcinoma", "Hepatocellular Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Nasopharyngeal Carcinoma", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Epithelial Ovarian Cancer", "Pancreatic Ductal Adenocarcinoma", "Soft Tissue Sarcoma", "Gastric Adenocarcinoma", "Malignant Mesothelioma (MM)", "Von Hippel Lindau", "Bladder Cancer", "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "89Zr-girentuximab for PET/CT imaging of CAIX positive tumors", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 11, "start_date": "2023-06-06", "completion_date": "2025-05-09", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-10-07T11:20:11.928Z", "location_count": 10, "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Traverse City", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05563272" }, { "nct_id": "NCT00002639", "title": "Suramin in Treating Patients With Recurrent Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "chemotherapy", "type": "DRUG" }, { "name": "suramin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": null, "start_date": "1995-07", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-10-07T11:20:11.928Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002639" }, { "nct_id": "NCT01148966", "title": "Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Mixed Glioma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "aminolevulinic acid", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-10-07T11:20:11.928Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01148966" }, { "nct_id": "NCT02039778", "title": "Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioblastoma", "Malignant Glioma", "Brain Tumors", "Anaplastic Astrocytoma" ], "interventions": [ { "name": "Stem Cell Radiotherapy (ScRT) and Temozolomide", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Beth Israel Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 4, "start_date": "2013-12", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-06-05", "last_synced_at": "2026-10-07T11:20:11.928Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02039778" }, { "nct_id": "NCT04573140", "title": "A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Glioblastoma", "High Grade Glioma", "WHO Grade III or IV Malignant Glioma" ], "interventions": [ { "name": "Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 28, "start_date": "2021-12-13", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-07T11:20:11.928Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Gainesville, Florida", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04573140" }, { "nct_id": "NCT00509431", "title": "Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "Erlotinib + Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2006-08", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2020-07-31", "last_synced_at": "2026-10-07T11:20:11.928Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509431" } ] }